The Zionist newspaper “The Times of Israel” in a report described “Albert Borla” CEO and chairman of “Pfizer” company as a fanatical Israeli.

Ron Dermer, the zionist regime’s ambassador in Washington, said that Albert Borla is an immigrant survivor of the alleged Holocaust, whose parents were among the Jews who allegedly escaped from the Nazis to Thessaloniki(Greece’s second-largest city).

The Zionist media “Jewish voice” also introduced him in an article as a New York resident from the Jews of Thessaloniki, Greece, who still has relatives there and visits them. According to this report, Mikael Dolsten, another senior executive at the Pfizer vaccination company, identified as a Swedish descent immigrant whose family fled Austria in the early days of World War II. Dolsten traveled to occupied Palestine several times when he was a young man and spent a year studying at the Wiseman Institute.

“The Times of Israel” describes Dolestan as a Jewish immigrant who left Sweden for New York in 2004.

The third person mentioned in the Zionist media reports is “Tal Zaks,” the senior medical director of “Moderna.”

According to these reports, he is an Israeli Zionist born in Haifa in occupied Palestine. He received his degree from Bangor University in occupied Palestine, then completed his additional research at the U.S. National Institutes of Health.

A recent survey found that thousands of U.S. health care workers are reluctant to receive the coronavirus vaccine because of its side effects. According to “Daily Mail,” 60% of an Elderly care center staff in Ohio, almost half of the health sector employees of an area in California, and 40% of the nurses in Los Angeles refuse to receive the coronavirus vaccine. These survey participants said: we are concerned about the dangerous side effects of receiving this vaccine and do not want to be treated as a laboratory mouse.

The American newspaper “U.S. Today” recently reported the death of an American doctor, Dr. Grogeri Michelle, who worked at Mount Sinai Medical Center in Miami Beach almost one week after receiving the Coronavirus vaccine.

“My husband was completely healthy and had no history of any disease, but he went to the emergency room three days after the Pfizer vaccine due to internal bleeding; my husband’s death was linked to the Pfizer vaccine,” said Heidi Neklman(the doctor’s wife.)

The Florida Department of Health said that Miami Medical Inspectors are investigating the death of the 56-year-old doctor.

Earlier, Sonia Asvido, a Portuguese health worker, died suddenly 48 hours after receiving the Pfizer coronavirus vaccine. The 41-year-old woman did not feel any side effects after receiving the “biontechPfizer” coronavirus vaccine on December 30 but died on January 1. In Norway, two women died after receiving the Pfizer vaccine too.

In addition to these reports, there have been numerous side effects among recipients of these vaccines.

According to another report, just a few days after distributing Pfizer’s coronavirus vaccine among people, several allergies and one case of coronavirus were reported.

The “New York Times” previously reported that two nurses in Alaska had become allergic to the Pfizer vaccine. One of the nurses, who had no history of allergies, developed an “anaphylactic” reaction just 10 minutes after receiving the vaccine. According to the newspaper, cases of allergies and side effects have already been reported among Pfizer vaccine recipients in the U.K.

However, U.S. President Donald Trump approved the Pfizer vaccine and distributed it in the country. Simultaneously, health officials warned that the necessary studies on this vaccine had not been completed yet.

According to the U.S. Department of Justice’s official website, Pfizer has recorded its history’s largest drug violation. According to the report, the U.S. justice system has so far received 74 Definitive convictions for the Pfizer company for: “endangering public health” to “concealment of product performance” or “fraud.”

Recently, the Supreme Leader of the Islamic Revolution, Ayatollah Khamenei, stressed that the importation of American and British coronavirus vaccines is prohibited. This order was met with positive publicity in Iran due to American and British vaccine companies’ negative records. However, some foreign media tried to make the statement look different; However, these actions were mitigated by exposing the consequences of using these vaccines.

The post Zionists who administer Pfizer and Moderna vaccine companies appeared first on News Agency nabakhabar.

Moderna is the second drugmaker to seek emergency use from the FDA after Pfizer, another front-runner in the Covid-19 vaccine race, applied for the same authorization on Nov. 20. The announcement means some Americans could get the first doses of Moderna’s two-dose vaccine within a few weeks.

The new analysis from Moderna evaluated 196 confirmed Covid infections among the late-stage trial’s 30,000 participants. The company said 185 cases of Covid were observed in the placebo group versus 11 cases observed in the group that received its vaccine. That resulted in an estimated vaccine efficacy of 94.1%, the company said.

The company released Nov. 16 an early analysis of its phase three trial based on just 95 Covid-19 cases that showed its vaccine was at least 94% effective. Monday’s data provides a complete picture of the vaccine’s effectiveness.

It also appears to prevent volunteers from getting severely sick from the virus. Of the 30 severe cases of Covid-19 in the trial, none were in the group that received the vaccine, Moderna said. Additionally, according to the company, there was one Covid-19 related death in the study that occurred in the placebo group.

Shares of Moderna were up more than 12% in premarket trading Monday.

“This positive primary analysis confirms the ability of our vaccine to prevent COVID-19 disease with 94.1% efficacy and, importantly, the ability to prevent severe COVID-19 disease. We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalizations, and death,” Moderna CEO Stephane Bancel said in a statement.

Moderna said the vaccine’s effectiveness was consistent across age, race, and gender. The 196 confirmed cases included 33 adults over 65 and 42 people from Black, Latino, and other “diverse” communities. The vaccine was also well-tolerated, with the most common side effects being fatigue, muscle pain, headache, and pain at the injection site, the company said.

Bancel told CNBC on Monday that the company expects to test the vaccine on children between the ages of 11 and 17 later this year. He added that testing on children under the age of 11 wouldn’t begin until sometime next year. “For younger children, you have to go down in age very slowly, and you have to start at a lower dose to make sure it is safe,” he said during an interview on “Squawk Box.”

Emergency use authorization means the FDA will allow some adults to receive the vaccine as the agency continues to evaluate data. It isn’t the same as a full approval, which can typically take months. The FDA granted emergency clearance for Gilead Sciences’ redeliver in May before giving full approval in late October.

According to data, Moderna’s results come as drugmakers and public health officials race to deliver a safe and effective vaccine to help bring an end to the pandemic, which has killed at least 1.45 million people worldwide as of Sunday evening compiled by Johns Hopkins University. Investors also see a vaccine as a way to get the global economy back on track after the virus wreaked havoc on nearly every country.

The FDA’s review of Moderna’s vaccine is expected to take a few weeks. The agency will likely schedule an advisory committee meeting to review the vaccine on Dec. 17, Moderna said. It has already initiated rolling submissions with several regulatory agencies worldwide, including the European Medicines Agency.

Federal agencies are already sending vaccination plans around to staff. Five agencies have started telling employees they could receive Pfizer’s or Moderna’s Covid-19 vaccine in as little as eight weeks, a person with firsthand knowledge of those plans told CNBC on Nov. 20.

Health and Human Services Secretary Alex Azar told CNBC on Nov. 16 that the FDA would move “as quickly as possible” to clear Pfizer’s and Moderna’s vaccines for emergency use. Between Moderna and Pfizer, Azar told CNBC there would be roughly 40 million doses of vaccine available by the end of this year, enough to inoculate about 20 million people since both vaccines require two shots, he said at the time.

Moderna’s initial results released earlier this month were based on the first interim efficacy analysis conducted by an external and independent data monitoring committee from the phase three clinical trial. The independent group of experts oversees U.S. clinical trials to ensure the safety of participants.

Public health officials and medical experts note it remains unclear how long the vaccines will provide immunity and whether or how often people may need periodic booster shots. Moderna’s vaccine, like Pfizer’s, uses messenger RNA, or mRNA, technology. It’s a new approach to vaccines that uses genetic material to provoke an immune response.

Cambridge, Massachusetts-based Moderna has said its vaccine remains stable at 36 to 46 degrees Fahrenheit, the temperature of a standard home or medical refrigerator, for up to 30 days. It can be stored for up to six months at negative 4 degrees Fahrenheit. By comparison, Pfizer’s vaccine requires a storage temperature of minus 94 degrees Fahrenheit.

Moderna told investors on Oct. 29 that it was “actively preparing” for the global launch of its potential vaccine after completing enrollment in its late-stage trial a week earlier. In August, Moderna said it was charging between $32 and $37 per dose for its vaccine for some customers, under cheaper “pandemic pricing.” The company said it was in discussion for larger volume agreements that will have a lower price.

The post Moderna says new data shows Covid vaccine is more than 94% effective, plans to ask FDA for emergency clearance later Monday appeared first on News Agency nabakhabar.